Whitehawk Therapeutics (WHWK) Consolidated Net Income (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Consolidated Net Income data on file, last reported at -$22.2 million in Q1 2026.

• On a quarterly basis, Consolidated Net Income fell 130.4% year-over-year to -$22.2 million in Q1 2026; TTM through Mar 2026 was -$124.9 million, a 532.98% decrease from a year earlier, with the FY2025 full-year figure at -$16.3 million, up 74.45% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$22.2 million, up from -$29.3 million in the prior quarter.
• Over the last five years, Consolidated Net Income for WHWK reached as high as $73.0 million in Q1 2025 and fell as low as -$55.2 million in Q2 2025.
• Historically, Consolidated Net Income has averaged -$14.2 million across 5 years, with a median of -$16.3 million in 2023.
• Across the five-year window, Consolidated Net Income plunged 1089.39% in 2022 and jumped 471.15% in 2025, its largest moves.
• Year by year, Consolidated Net Income stood at -$13.9 million in 2022, then declined by 16.93% to -$16.3 million in 2023, then increased by 4.84% to -$15.5 million in 2024, then slumped by 89.28% to -$29.3 million in 2025, then advanced by 24.26% to -$22.2 million in 2026.
• Per Business Quant data, the three most recent Consolidated Net Income figures were -$22.2 million in Q1 2026, -$29.3 million in Q4 2025, and -$18.2 million in Q3 2025.